Von Willebrand, HIT, DIC and anticoagulant assays
15 min
- Classify a von Willebrand panel from antigen, activity ratio, and factor VIII
- Sequence HIT immunoassay and functional testing by pretest probability
- Recognize the platelet, PT, D-dimer, and fibrinogen changes that suggest DIC
- Choose the calibrated assay that measures a stated heparin or direct oral anticoagulant
Try first
Get the idea
Classifying a VWF panel
The initial VWD panel combines VWF antigen, platelet-dependent VWF activity, and factor VIII activity. An activity-to-antigen ratio below 0.7 supports a qualitative type 2 defect. A ratio at or above 0.7, with both values proportionately reduced, fits type 1. Multimer analysis or collagen-binding activity then separates the type 2 subtypes.1
HIT testing follows pretest probability
The 4Ts score weighs thrombocytopenia depth, timing after heparin exposure, thrombosis, and competing causes. With an intermediate or high score, a PF4-heparin immunoassay screens first. A positive immunoassay shows binding antibody. A functional assay, such as the serotonin-release assay, shows activation at a low heparin concentration that saturating heparin suppresses, and that heparin-dependent pattern is what confirms heparin-induced thrombocytopenia (HIT).2
DIC is read from the whole pattern
Disseminated intravascular coagulation (DIC) needs a compatible trigger together with falling platelets, a lengthening prothrombin time (PT), a raised D-dimer, and falling fibrinogen. The 2025 International Society on Thrombosis and Haemostasis (ISTH) score scales each component against the assay's own D-dimer upper limit of normal, and a total of 5 or more is compatible with overt DIC in the right setting.3 A single raised D-dimer, without the trigger and the other changes, overcalls DIC.
Matching the anticoagulant to its assay
Anti-Xa results are quantitative only against the drug's own calibrator. A heparin-calibrated anti-Xa assay falsely raises a result for apixaban or rivaroxaban, and neither the PT nor the APTT can quantify either drug.4 A drug-calibrated anti-Xa assay measures direct factor Xa inhibitors, and a dilute thrombin time or an ecarin-based assay measures dabigatran.
References
- James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5(1):280-300. doi:10.1182/bloodadvances.2020003265
- Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360-3392. doi:10.1182/bloodadvances.2018024489
- Iba T, Levy JH, Maier CL, et al. Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation. J Thromb Haemost. 2025;23(7):2356-2362. doi:10.1016/j.jtha.2025.03.038
- Douxfils J, Adcock DM, Bates SM, et al. 2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost. 2021;121(8):1008-1020. doi:10.1055/a-1450-8178
Watch one
A patient's platelet count has fallen more than 50% from baseline, with a nadir of 35 × 10³/µL, beginning 7 days after starting unfractionated heparin for a different indication. No other cause of thrombocytopenia is apparent.
- Score the 4Ts: a fall greater than 50% with this nadir, this timing, and no competing cause gives an intermediate or high score.
The 4Ts score weighs exactly these features and sets the pretest probability before any testing begins.
- Decide to test, since the score is intermediate or high.
Testing at a low pretest probability risks a false-positive antibody result being treated as HIT, so the score decides whether to test at all.
- Order the PF4-heparin immunoassay first.
The immunoassay is broad and sensitive, a reasonable first test, but it detects binding antibody whether or not that antibody activates platelets.
- If the immunoassay is positive, order a functional assay, such as the serotonin-release assay, before treating the result as confirmed HIT.
Only a functional assay shows the heparin-dependent activation pattern that separates a platelet-activating antibody from one that is not.
Your turn
Use it
- A woman with metastatic adenocarcinoma and new sepsis (MRN 0083517) has a coagulation and platelet panel ordered from the intensive care unit.
- She has no history of a bleeding or platelet disorder.
- She was started on prophylactic heparin 3 days ago.
| Test | Result | Previous | Reference interval | Flag |
|---|---|---|---|---|
| Platelet count | 38 × 10³/µL | 165 × 10³/µL3 days ago | 150–450 × 10³/µL | Low |
| PT | 17.2 s | 12.9 s3 days ago | 11.5–14.5 s | High |
| Fibrinogen | 92 mg/dL | 310 mg/dL3 days ago | 200–400 mg/dL | Low |
| D-dimer | 9 × ULN | <1 × ULN × ULN | High |
Specimen: H 4, L 6, I 2. Citrate plasma and EDTA whole blood, both correctly filled.
The clue that settles this case is the trend across the panel and its repeat: platelets and fibrinogen both falling, with a high D-dimer and a lengthening PT, against a compatible trigger of sepsis. That combination is the pattern the DIC score is built to capture.
Results
- Classify a von Willebrand panel from antigen, activity ratio, and factor VIII
- Sequence HIT immunoassay and functional testing by pretest probability
- Recognize the platelet, PT, D-dimer, and fibrinogen changes that suggest DIC
- Choose the calibrated assay that measures a stated heparin or direct oral anticoagulant
To review
6 questions from this step will come back in Review.
Next step: Pipettes, glassware and temperature checksReview nowOpen the part
Keep
Sources checked
The rest of this step
A short briefing, a demonstration at the bench, 3 practice problems and a short case.
A free account opens the rest and keeps your progress.